Business

Eli Lilly adds preclinical Alzheimer's candidate through USD 1b deal with AlzeCure

Edited by Robert McTiernan··3 min read
Eli Lilly adds preclinical Alzheimer's candidate through USD 1b deal with AlzeCure

Eli Lilly has agreed to license global rights to Alzstatin ACD680, a preclinical small-molecule gamma-secretase modulator for Alzheimer's disease, from Sweden-based AlzeCure Pharma AB (STO: ALZCUR), in a deal worth up to USD 1 billion excluding royalties. The transaction gives Lilly worldwide development and commercialization rights to the compound and adds a mechanistically distinct amyloid-targeting approach to a neuroscience portfolio that already includes the approved anti-amyloid antibody donanemab (Kisunla).

Under the terms, AlzeCure receives a USD 10 million upfront payment, tiered mid-single-digit royalties on net sales, and development and commercial milestones that could push the total deal value beyond USD 1 billion. Specific milestone triggers and individual payment amounts were not disclosed. The transaction is subject to closing conditions including approval by Swedish authorities under foreign direct investment regulations.

Deal context

Alzstatin ACD680 (AC-0027875) is a small-molecule gamma-secretase modulator (GSM) described by AlzeCure as capable of reducing production of the toxic amyloid-beta peptide Aβ42 while simultaneously increasing shorter, less aggregation-prone variants Aβ37 and Aβ38. The compound works by allosterically shifting the cleavage preference of the gamma-secretase enzyme complex rather than blocking the enzyme outright — a design intended to preserve Notch signaling and avoid the severe toxicities that caused earlier gamma-secretase inhibitors such as semagacestat to fail in Phase III.

The mechanistic distinction from Lilly's existing portfolio is material. Donanemab clears amyloid plaques that have already formed; ACD680 is positioned to reduce Aβ42 production upstream, before aggregation occurs. AlzeCure has described the Alzstatin program as potentially suited to both disease modification and prevention, though no clinical data have been generated. The compound remains preclinical, and Lilly will assume responsibility for clinical development and commercialization following closing.

The Alzstatin platform has a documented genetic rationale: AlzeCure's chief scientific officer noted in the announcement that gamma-secretase modulators carry a strong genetic link to Alzheimer's disease, referencing the well-established connection between presenilin mutations — which alter gamma-secretase cleavage — and familial Alzheimer's.

Industry and transaction context

The USD 10 million upfront payment is modest relative to recent Alzheimer's-focused licensing transactions, reflecting the asset's preclinical stage. By comparison, when Rockville, Maryland-based SciNeuro Pharmaceuticals licensed an amyloid-beta antibody program to Novartis in January 2026, SciNeuro received USD 165 million upfront against a total potential value of up to USD 1.5 billion — a deal involving a more advanced antibody program with blood-brain barrier shuttle technology.

The AllSci BriefSystematic R&D and deal news. Daily.

Lilly has been an active acquirer of CNS and neurodegenerative disease assets across modalities. In April 2026, Lilly amended its Tau collaboration with AC Immune, paying a CHF 10 million (USD 12.5 million) upfront fee to extend coverage to new oral small-molecule Tau aggregation inhibitors.

The structural choice to license a preclinical GSM rather than an antibody is notable given the crowded anti-amyloid antibody landscape. The approvals of lecanemab and donanemab — both anti-amyloid biologics requiring infusion — have validated the amyloid hypothesis but left room for differentiated approaches, particularly oral small molecules that could address earlier-stage or prevention-oriented populations. The GSM class has not produced an approved drug, but the mechanistic rationale has been rehabilitated following the Notch-toxicity failures of first-generation gamma-secretase inhibitors, and the AlzeCure deal suggests Lilly sees the approach as worth clinical evaluation.

For AlzeCure, the transaction represents the first major out-licensing of its Alzstatin platform and provides non-dilutive capital and validation for a company whose market capitalization on Nasdaq First North has remained small. AlzeCure retains its NeuroRestore and Painless platforms, which include separate CNS and pain assets not covered by the Lilly agreement.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/

Spot something wrong? Report an issue with this article